lung

individualized neoantigen mRNA vaccine plus anti-PD-1 antibody

Thesis

[KNOWN] The evidence pack reports T-cell responses to individualized neoantigen therapy with V940 alone or with pembrolizumab in the KEYNOTE-603 Phase 1 study. [INFERRED] In lung cancer, the next test should select patients with resectable or measurable tumors carrying sufficient predicted clonal neoantigens and evaluate whether vaccination broadens or sustains tumor-reactive T-cell responses. [INFERRED] Falsification would be immune responses without a corresponding improvement in measurable minimal residual disease or tumor control.

Mechanism

[KNOWN] Individualized mRNA vaccination is intended to present patient-specific neoantigens and expand corresponding T-cell populations. [KNOWN] Pembrolizumab blocks PD-1 signaling. [INFERRED] Combining antigen priming with checkpoint release could improve responses in tumors that contain relevant neoantigens but lack effective T-cell expansion.

Kill experiment

Run a small randomized, biomarker-selected lung-cancer window trial with paired baseline and post-treatment blood/tumor samples. If V940 plus pembrolizumab produces no reproducible predicted-neoantigen-specific T-cell expansion and no minimal-residual-disease or tumor-control increment over pembrolizumab, the hypothesis is falsified.

anti-PD-1 monoclonal antibody

Thesis

[KNOWN] Pembrolizumab is an established immunotherapy for multiple non-small-cell lung cancer settings. [INFERRED] The most testable increment is biomarker-enriched evaluation in tumors with high PD-L1 expression, high tumor mutational burden, or an inflamed immune microenvironment. [INFERRED] Falsification would be failure to observe a predefined response or survival signal in a prospectively selected cohort.

Mechanism

[KNOWN] PD-1 blockade can restore activity of functionally suppressed antitumor T cells. [INFERRED] Benefit should depend on pre-existing tumor-reactive immunity rather than PD-1 expression alone.

Kill experiment

In a prospectively selected lung-cancer cohort, failure to show a predefined response-rate, progression-free-survival, or overall-survival signal versus the relevant standard, despite confirmed drug exposure, kills the proposed biomarker increment.

Why it died

The pack defines only the unresolved term "lung" and supplies no evidence that the disease is PD-L1-positive NSCLC or any malignancy. This is an established NSCLC treatment, not an unreviewed hypothesis for the queried disease. The causal chain stops at PD-1 blockade: no lung disease mutation, tumor-specific antigen, immune defect, or link from restored T-cell function to symptoms is established here.

third-generation EGFR tyrosine kinase inhibitor

Thesis

[KNOWN] Osimertinib is an established treatment for EGFR-mutated non-small-cell lung cancer. [INFERRED] It should be prioritized only in molecularly confirmed EGFR-driven disease, with resistance mechanisms used to select the next combination or sequencing strategy. [INFERRED] Falsification would be lack of genotype-dependent activity or inability to delay a molecularly defined resistance clone.

Mechanism

[KNOWN] Osimertinib inhibits activating EGFR signaling and has activity against the EGFR T790M resistance alteration. [INFERRED] Residual disease after response may be used to identify bypass signaling or lineage plasticity before combination selection.

Kill experiment

In molecularly confirmed EGFR-driven lung cancer, absence of genotype-dependent activity or failure of the proposed resistance-directed strategy to delay a predefined molecular or clinical resistance endpoint kills the hypothesis.

Why it died

Osimertinib requires molecularly confirmed activating EGFR disease, but the evidence pack reports no EGFR alteration, target association, or even a lung-cancer diagnosis. The chain from mutation to EGFR dependence to tumor burden and lung symptoms is entirely assumed. It is an established EGFR-mutant NSCLC treatment rather than an unreviewed hypothesis for generic lung disease.

covalent KRAS G12C inhibitor

Thesis

[KNOWN] Adagrasib has clinical activity in KRAS G12C-mutated non-small-cell lung cancer. [INFERRED] A useful next increment is resistance-guided combination testing in tumors showing MAPK pathway recovery or persistence of a KRAS-dependent state. [INFERRED] Falsification would be no association between the proposed resistance signature and loss of response.

Mechanism

[KNOWN] Adagrasib binds KRAS G12C and suppresses signaling from the mutant protein. [INFERRED] Adaptive pathway reactivation may limit durability and can be tested using paired pretreatment and progression samples.

Kill experiment

Paired pretreatment and progression samples showing no reproducible association between the proposed MAPK-recovery or KRAS-dependence signature and loss of response kills the resistance-guided hypothesis.

Why it died

Adagrasib is specific to KRAS G12C-mutated NSCLC, yet no KRAS G12C alteration or NSCLC subtype is present in the pack. The required chain from KRAS G12C dependence to malignant growth, lung symptoms, and suppression by covalent KRAS inhibition is missing. The proposed resistance-guided increment is an extension of an established treatment, not an unreviewed mechanism for the queried disease.

DNA methyltransferase inhibitor plus anti-PD-1 antibody

Thesis

[KNOWN] Azacitidine is an approved hypomethylating agent, and the evidence pack discusses endogenous retrovirus-directed immune mechanisms in lung cancer immunotherapy. [INFERRED] In a biomarker-selected lung cancer cohort, azacitidine could be tested as an immune-priming repurposing strategy before checkpoint blockade. [SPECULATIVE] The combination may increase viral-mimicry signals and improve checkpoint sensitivity. [INFERRED] Falsification would be absence of the predicted viral-mimicry and T-cell activation signatures together with no clinical increment.

Mechanism

[KNOWN] DNA methyltransferase inhibition can alter transcriptional silencing. [INFERRED] Reactivation of endogenous retroviral elements could generate innate immune signaling or antigenic features that make tumors more visible to T cells. [SPECULATIVE] This mechanism will not be effective if the relevant endogenous-retrovirus loci, sensing pathways, or antigen-presentation machinery are defective.

Kill experiment

Before efficacy testing, measure endogenous-retrovirus transcription, innate sensing, antigen presentation, and T-cell activation in lung tumor models or biopsies after azacitidine. Kill the hypothesis if these signatures do not increase at tolerated exposure or if a biomarker-selected randomized comparison shows no clinical increment over pembrolizumab alone.

Why it died

The pack contains no azacitidine evidence or lung-specific azacitidine-pembrolizumab trial. PMID 37046094 concerns antibodies against endogenous retroviruses, not DNA-methyltransferase inhibition. The claims that azacitidine is relevant here and will reactivate the required endogenous-retrovirus loci are not supported as [KNOWN]; the central bridge from ERV biology to this combination is missing and remains speculative.

anti-PD-1 plus anti-CTLA-4 monoclonal antibodies

Thesis

[KNOWN] Dual PD-1 and CTLA-4 blockade is an established immunotherapy approach in selected non-small-cell lung cancer settings. [INFERRED] A next increment is to test whether baseline tumor inflammation, neoantigen burden, and peripheral T-cell clonality identify patients who gain from dual blockade over PD-1 blockade alone. [INFERRED] Falsification would be no predictive value from these immune features or no incremental efficacy that justifies the added toxicity.

Mechanism

[KNOWN] PD-1 blockade acts predominantly on exhausted T-cell function, while CTLA-4 blockade can increase T-cell priming and activation. [INFERRED] Their combination may be useful when lung tumors have both inadequate priming and dysfunctional intratumoral T cells.

Kill experiment

Against PD-1 blockade alone in the defined lung-cancer population, failure of the proposed baseline immune features to predict benefit, or failure of dual blockade to produce a clinically meaningful benefit that outweighs added toxicity, kills the hypothesis.

Why it died

The pack provides no defined lung disease, tumor mutation, antigen-presentation defect, or immune phenotype establishing that dual checkpoint blockade addresses the queried condition. The proposed chain from inadequate priming plus intratumoral dysfunction to CTLA-4/PD-1 sensitivity is conjectural, while the combination is already an established approach in selected NSCLC settings rather than an unreviewed hypothesis. Baseline immune correlates are not a causal mechanism and do not connect to lung symptoms.

oral biguanide repurposing candidate

Thesis

[KNOWN] Metformin is an established antidiabetic drug, but its anticancer benefit in lung cancer is not established by the supplied evidence pack. [SPECULATIVE] Metformin could alter tumor-cell metabolism or immune-cell function in a subset of metabolically stressed lung tumors. [INFERRED] It should be evaluated only with pharmacodynamic biomarkers and randomized comparison against standard therapy. [INFERRED] Falsification would be no exposure-linked metabolic or immune change and no improvement in a prespecified clinical endpoint.

Mechanism

[KNOWN] Metformin affects cellular energy metabolism through pathways including AMP-activated protein kinase signaling. [SPECULATIVE] Those effects may reduce fitness of metabolically constrained tumor cells or improve antitumor immunity, but the relevant mechanism and patient subgroup remain unproven.

Why it died

Although metformin exists, the pack supplies no lung-cancer-specific clinical, target, or trial evidence and explicitly concedes that anticancer benefit in lung cancer is unestablished. The proposed mechanism is a generic metabolic speculation with no identified lung-cancer dependency or exposure-feasible pharmacodynamic link; a randomized study is not a cheap triage experiment that establishes the missing premise.